Your browser doesn't support javascript.
loading
Population-wide eGFR percentiles in younger adults and clinical outcomes.
Hussain, Junayd; Imsirovic, Haris; Talarico, Robert; Akbari, Ayub; Ravani, Pietro; Tanuseputro, Peter; Hundemer, Gregory L; Ramsay, Tim; Tangri, Navdeep; Knoll, Greg A; Bugeja, Ann; Sood, Manish M.
Afiliação
  • Hussain J; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, CANADA.
  • Imsirovic H; Institute of Clinical Evaluative Sciences (ICES), Ottawa, Ontario, CANADA.
  • Talarico R; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, CANADA.
  • Akbari A; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, CANADA.
  • Ravani P; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, CANADA.
  • Tanuseputro P; Division of Nephrology, Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, CANADA.
  • Hundemer GL; Department of Medicine, University of Calgary, Calgary, Alberta, CANADA.
  • Ramsay T; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, CANADA.
  • Tangri N; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, CANADA.
  • Knoll GA; Institute of Clinical Evaluative Sciences (ICES), Ottawa, Ontario, CANADA.
  • Bugeja A; Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, CANADA.
  • Sood MM; Institute of Clinical Evaluative Sciences (ICES), Ottawa, Ontario, CANADA.
Article em En | MEDLINE | ID: mdl-39013603
ABSTRACT
BACKGROUND AND

HYPOTHESIS:

Identifying meaningful estimated glomerular filtration rate (eGFR) reductions in younger adults (<65 years) could guide prevention efforts. To aid in interpretation and identification of young adults at risk, we examined the association of population-level eGFR percentiles relative to the median by age and clinical outcomes.

METHODS:

We conducted a retrospective cohort study of 8.7 million adults from Ontario, Canada from age 18 to 65 from 2008 to 2021 with an eGFR measure (both single outpatient value and repeat measures). We calculated median eGFR values by age and examined the association of reduced eGFR percentiles (≤10th, 5th, 2.5th and 1st) with outcomes using time to event models. Outcomes were a composite of all-cause mortality, major adverse cardiac outcomes (MACE) with/without heart failure (MACE+) and kidney failure as well as each component individually.

RESULTS:

From age 18 to 65, the median eGFR declined with age (range 128 to 90) and across percentiles [eGFR ranges 102 to 68 for ≤10th, 96 to 63 for ≤5th, 90 to 58 for ≤2.5th and 83 to 54 for 1st]. The adjusted rate for any adverse outcome was elevated at ≤ 10th percentile (HR 1.14 95%CI 1.10-1.18) and was consistent for all-cause mortality, MACE, MACE+ and predominant for kidney failure (HR 5.57 95%CI 3.79-8.19) compared to the median eGFR for age. Young adults with an eGFR in the lower percentiles were less likely to be referred to a specialist, have a repeat eGFR or albumin to creatinine ratio measure.

CONCLUSIONS:

eGFR values at the 10th percentile or lower based on a population-level distribution are associated with adverse clinical outcomes and in younger adults (18 to 39) this corresponds to a higher level of eGFR that may be underrecognized. Application of population-based eGFR percentiles may aid interpretation and improve identification of younger adults at risk.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article